You are here

Pre-Clinical Development of Topical Pirenzepine for Treating Diapetic Neuropathy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44DK104512-01
Agency Tracking Number: R44DK104512
Amount: $371,908.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA14-055
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4685 CONVOY ST, # 210
SAN DIEGO, CA 92111-2339
United States
DUNS: 78868444
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANGELA HANSEN
 (858) 336-8094
 ahansen@winsantorbio.com
Business Contact
 STANLEY KIM
Phone: (858) 336-8094
Email: skim@winsantorbio.com
Research Institution
 Stub
Abstract

? DESCRIPTION (provided by applicant): The objective of this SBIR fast-track project is to expediently advance pre-clinical development of a new therapeutic for diabetic neuropathy. Of the 25 million Americans who suffer from diabetes, approximately 50% will be diagnosed with neuropathy, which is characterized by nerve degeneration. Despite the high prevalence of the disease, there is currently no FDA-approved treatment to either prevent diabetes-induced nerve degeneration or promote nerve regeneration.Thus, there is a substantial unmet need to develop more effective treatments for diabetic neuropathy. The founders of WinSanTor have identified a promising candidate which both prevents and reverses neuropathy in rodent models of the disease. The candidate molecule, pirenzepine, was identified using a novel screening methodology developed in the labs of the company's founders. Pirenzepine has subsequently been evaluated in over a dozen in vivo tests, and has demonstrated the unique ability to ameliorate bo

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government